ArticleThe MAK collection for occupational health and safety2025
Aluminium - Addendum: re-evaluation of the BAT Value and assignment to a pregnancy risk group: Assessment Values in Biological Material - Translation of the German version from 2025.
Article in The MAK collection for occupational health and safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selected medium-chain dicarboxylic acids: alternative preservatives in improving shelf-life and quality of meat products.Food science and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The German Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (MAK Commission) re-evaluated the data for aluminium [7429-90-5] to verify the biological tolerance value (BAT value) of 50 μg aluminium/g creatinine in urine and assign it to a pregnancy risk group. Relevant studies were identified from a literature search. In the previous evaluation, neurotoxic effects were considered the most sensitive systemic endpoint of aluminium and a BAT value of 50 μg aluminium/g creatinine was derived from a no observed adverse effect level (NOAEL) of 50 μg/g creatinine for the occurrence of preclinical neurotoxic effects in humans, which was determined by standardised neuropsychological test procedures in workplace studies. As the BAT value is thus well-founded and there are no more recent data that would call this into question, the BAT value for aluminium is confirmed. Sampling time is at the end of the shift, for long-term exposures after several previous shifts. There are no reliable studies available to assess the developmental toxicity and developmental neuroxicity of aluminium compounds in humans. There is no evidence that children are more sensitive to aluminium-induced neurotoxic effects than adults. In animal studies, aluminium concentrations in the urine of pregnant animals have not been determined and it is not known at which blood concentration developmental toxic or developmental neurotoxic effects occur in animals. There are also uncertainties regarding the transfer of animal data to humans. Therefore, a reliable risk assessment for developmental toxicity and developmental neurotoxicity is not possible and with regard to the BAT value of 50 µg aluminium/g creatinine, aluminium is assigned to Pregnancy Risk Group D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.